Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Pulmonary Therapy|June 23, 2026
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled TrialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 24, 2025
Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific RegionQingling Zhang, Nanshan Zhong, Sahajal Dhooria, et al.
JAMA Dermatology|February 18, 2026
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical TrialsThomas B Casale, Sarbjit S Saini, Moshe Ben-Shoshan, et al.
JAMA Network Open|October 26, 2021
Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 VaccinationLily Li, Lacey B Robinson, Rajesh Patel, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Respiratory Medicine|October 31, 2024
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The New England Journal of Medicine|May 20, 2024
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Pageof 4